VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q109939935  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000245.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q109939935‏
035 ‎‡a  (OCoLC)Q109939935‏
100 0 ‎‡a  Heather Hill‏ ‎‡9  en‏ ‎‡9  nl‏
670 ‎‡a  Author's 994. AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Peripheral Blood Mononuclear Cells‏
670 ‎‡a  Author's A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA.‏
670 ‎‡a  Author's A Phase II Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide -Tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization with GBS III‏
670 ‎‡a  Author's Alkaline CPD and the preservation of RBC 2,3-DPG.‏
670 ‎‡a  Author's Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy.‏
670 ‎‡a  Author's Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine‏
670 ‎‡a  Author's Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial‏
670 ‎‡a  Author's Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine‏
670 ‎‡a  Author's Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.‏
670 ‎‡a  Author's Clinical and immunologic responses to multiple doses of IMVAMUNE‏
670 ‎‡a  Author's Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge‏
670 ‎‡a  Author's Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects‏
670 ‎‡a  Author's Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults‏
670 ‎‡a  Author's Determination of the 50% human infectious dose for Norwalk virus‏
670 ‎‡a  Author's Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes‏
670 ‎‡a  Author's Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis‏
670 ‎‡a  Author's Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial‏
670 ‎‡a  Author's Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults‏
670 ‎‡a  Author's Enhanced Potency and Durability of Antibody Response to Seasonal Trivalent Inactivated Influenza Vaccine‏
670 ‎‡a  Author's Enhanced Potency and Durability of Antibody Response to Seasonal Trivalent Inactivated Influenza Vaccine (TIV) Combined with a Novel Water-in-Oil Adjuvant System at Reduced Hemagglutinin (HA) Doses.‏
670 ‎‡a  Author's Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine‏
670 ‎‡a  Author's High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial‏
670 ‎‡a  Author's Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.‏
670 ‎‡a  Author's Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older‏
670 ‎‡a  Author's Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults‏
670 ‎‡a  Author's Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons‏
670 ‎‡a  Author's Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial‏
670 ‎‡a  Author's Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.‏
670 ‎‡a  Author's Low-dose aspirin use does not diminish the immune response to monovalent H1N1 influenza vaccine in older adults‏
670 ‎‡a  Author's Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant‏
670 ‎‡a  Author's Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals‏
670 ‎‡a  Author's Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations‏
670 ‎‡a  Author's Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine‏
670 ‎‡a  Author's PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4(+) T cell transcriptomal molecular signatures‏
670 ‎‡a  Author's Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial‏
670 ‎‡a  Author's Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination‏
670 ‎‡a  Author's Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination‏
670 ‎‡a  Author's Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.‏
670 ‎‡a  Author's RBC storage for 11 weeks‏
670 ‎‡a  Author's Retrospective Analysis of Pneumonic Tularemia in Operation Whitecoat Human Subjects: Disease Progression and Tetracycline Efficacy‏
670 ‎‡a  Author's RSEQREP: RNA-Seq Reports, an open-source cloud-enabled framework for reproducible RNA-Seq data processing, analysis, and result reporting‏
670 ‎‡a  Author's Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations‏
670 ‎‡a  Author's Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial‏
670 ‎‡a  Author's Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.‏
670 ‎‡a  Author's Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults‏
670 ‎‡a  Author's Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old‏
670 ‎‡a  Author's Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.‏
670 ‎‡a  Author's Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.‏
670 ‎‡a  Author's Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.‏
670 ‎‡a  Author's Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario‏
670 ‎‡a  Author's Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults‏
670 ‎‡a  Author's Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant‏
670 ‎‡a  Author's Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.‏
670 ‎‡a  Author's Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant‏
670 ‎‡a  Author's Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial‏
670 ‎‡a  Author's Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine‏
670 ‎‡a  Author's Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses‏
670 ‎‡a  Author's The effect of two additive solutions on the postthaw storage of RBCs‏
670 ‎‡a  Author's The effects of phosphate, pH, and AS volume on RBCs stored in saline-adenine-glucose-mannitol solutions‏
670 ‎‡a  Author's The effects of polyvinyl chloride and polyolefin blood bags on red blood cells stored in a new additive solution‏
670 ‎‡a  Author's The role of electrolytes and pH in RBC ASs.‏
670 ‎‡a  Author's The viability of autologous human red cells stored in additive solution 5 and exposed to 25 degrees C for 24 hours‏
670 ‎‡a  Author's Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial‏
670 ‎‡a  Author's Twelve-week RBC storage‏
919 ‎‡a  12weekrbcstorage‏ ‎‡A  Twelve-week RBC storage‏ ‎‡9  1‏
919 ‎‡a  tularemiavaccinesafetyreactogenicitytakeskinreactionsandantibodyresponsesfollowingvaccinationwithanewlotofthefrancisellatularensislivevaccinestrainaphase2randomizedclinicaltrial‏ ‎‡A  Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial‏ ‎‡9  1‏
919 ‎‡a  viabilityofautologoushumanredcellsstoredinadditivesolution5andexposedto25degrees100for24hours‏ ‎‡A  The viability of autologous human red cells stored in additive solution 5 and exposed to 25 degrees C for 24 hours‏ ‎‡9  1‏
919 ‎‡a  roleofelectrolytesandphinrbcass‏ ‎‡A  The role of electrolytes and pH in RBC ASs.‏ ‎‡9  1‏
919 ‎‡a  effectsofpolyvinylchlorideandpolyolefinbloodbagsonredbloodcellsstoredinanewadditivesolution‏ ‎‡A  The effects of polyvinyl chloride and polyolefin blood bags on red blood cells stored in a new additive solution‏ ‎‡9  1‏
919 ‎‡a  effectsofphosphatephandasvolumeonrbcsstoredinsalineadenineglucosemannitolsolutions‏ ‎‡A  The effects of phosphate, pH, and AS volume on RBCs stored in saline-adenine-glucose-mannitol solutions‏ ‎‡9  1‏
919 ‎‡a  effectof2additivesolutionsonthepostthawstorageofrbcs‏ ‎‡A  The effect of two additive solutions on the postthaw storage of RBCs‏ ‎‡9  1‏
919 ‎‡a  systemsvaccinologyforaliveattenuatedtularemiavaccinerevealsuniquetranscriptionalsignaturesthatpredicthumoralandcellularimmuneresponses‏ ‎‡A  Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses‏ ‎‡9  1‏
919 ‎‡a  sexdifferenceinimmuneresponsetovaccinationaparticipantlevelmetaanalysisofrandomizedtrialsofimvamunesmallpoxvaccine‏ ‎‡A  Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine‏ ‎‡9  1‏
919 ‎‡a  serologicalresponsestoanavianinfluenzaah7n9vaccinemixedatthepointofusewithmf59adjuvantarandomizedclinicaltrial‏ ‎‡A  Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial‏ ‎‡9  1‏
919 ‎‡a  safetyreactogenicityandimmunogenicityofinactivatedmonovalentinfluenzaah5n1virusvaccineadministeredwithorwithoutas03adjuvant‏ ‎‡A  Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant‏ ‎‡9  1‏
919 ‎‡a  safetyandimmunogenicityofmodifiedvacciniaankarainhematopoieticstemcelltransplantrecipientsarandomizedcontrolledtrial‏ ‎‡A  Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.‏ ‎‡9  1‏
919 ‎‡a  safetyandimmunogenicityofinfluenzaah5subunitvaccineseffectofvaccinescheduleandantigenicvariant‏ ‎‡A  Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant‏ ‎‡9  1‏
919 ‎‡a  safetyandimmunogenicityofinactivatedverocellculturederivedwholevirusinfluenzaah5n1vaccinegivenaloneorwithaluminumhydroxideadjuvantinhealthyadults‏ ‎‡A  Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults‏ ‎‡9  1‏
919 ‎‡a  safetyandimmunogenicityofimvamunesmallpoxvaccineusingdifferentstrategiesforaposteventscenario‏ ‎‡A  Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario‏ ‎‡9  1‏
919 ‎‡a  safetyandimmunogenicityofhcve1e2vaccineadjuvantedwithmf59administeredtohealthyadults‏ ‎‡A  Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.‏ ‎‡9  1‏
919 ‎‡a  safetyandimmunogenicityoffulldosetrivalentinactivatedinfluenzavaccinetivcomparedwithhalfdosetivadministeredtochildren6through35monthsofage‏ ‎‡A  Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.‏ ‎‡9  1‏
919 ‎‡a  safetyandimmunogenicityofaninactivatedinfluenzaah5n1vaccinegivenwithorwithoutaluminumhydroxidetohealthyadultsresultsofaphase12randomizedclinicaltrial‏ ‎‡A  Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.‏ ‎‡9  1‏
919 ‎‡a  safetyandimmunogenicityofasubvirionmonovalentunadjuvantedinactivatedinfluenzaah3n2variantvaccineinhealthypersons18yearsold‏ ‎‡A  Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old‏ ‎‡9  1‏
919 ‎‡a  safetyandimmunogenicityofasubvirioninactivatedinfluenzaah5n1vaccinewithorwithoutaluminumhydroxideamonghealthyelderlyadults‏ ‎‡A  Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults‏ ‎‡9  1‏
919 ‎‡a  safetyandimmunogenicityofasinglelowdoseorhighdoseofclade2influenzaah5n1inactivatedvaccineinadultspreviouslyprimedwithclade1influenzaah5n1vaccine‏ ‎‡A  Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.‏ ‎‡9  1‏
919 ‎‡a  safetyandimmunogenicityofamodifiedvacciniaankaravaccineusing3immunizationschedulesand2modesofdeliveryarandomizedclinicalnoninferioritytrial‏ ‎‡A  Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial‏ ‎‡9  1‏
919 ‎‡a  safetyandimmuneresponsesinchildrenafterconcurrentorsequential2009h1n1and20092010seasonaltrivalentinfluenzavaccinations‏ ‎‡A  Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations‏ ‎‡9  1‏
919 ‎‡a  rseqreprnaseqreportsanopensourcecloudenabledframeworkforreproduciblernaseqdataprocessinganalysisandresultreporting‏ ‎‡A  RSEQREP: RNA-Seq Reports, an open-source cloud-enabled framework for reproducible RNA-Seq data processing, analysis, and result reporting‏ ‎‡9  1‏
919 ‎‡a  retrospectiveanalysisofpneumonictularemiainoperationwhitecoathumansubjectsdiseaseprogressionandtetracyclineefficacy‏ ‎‡A  Retrospective Analysis of Pneumonic Tularemia in Operation Whitecoat Human Subjects: Disease Progression and Tetracycline Efficacy‏ ‎‡9  1‏
919 ‎‡a  rbcstoragefor11weeks‏ ‎‡A  RBC storage for 11 weeks‏ ‎‡9  1‏
919 ‎‡a  qualificationofthehemagglutinationinhibitionassayinsupportofpandemicinfluenzavaccinelicensure‏ ‎‡A  Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.‏ ‎‡9  1‏
919 ‎‡a  proteomicsshowantigenpresentationprocessesinhumanimmunecellsafteras03h5n1vaccination‏ ‎‡A  Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination‏ ‎‡9  1‏
919 ‎‡a  primingvaccinationwithinfluenzavirush5hemagglutininantigensignificantlyincreasesthedurationoftcellresponsesinducedbyaheterologoush5boostervaccination‏ ‎‡A  Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination‏ ‎‡9  1‏
919 ‎‡a  pointofusemixingofinfluenzah5n1vaccineandmf59adjuvantforpandemicvaccinationpreparednessantibodyresponsesandsafetyaphase1clinicaltrial‏ ‎‡A  Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial‏ ‎‡9  1‏
919 ‎‡a  poandidbcgvaccinationinhumansinducedistinctmucosalandsystemicimmuneresponsesandcd4+tcelltranscriptomalmolecularsignatures‏ ‎‡A  PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4(+) T cell transcriptomal molecular signatures‏ ‎‡9  1‏
919 ‎‡a  plasmablastmemorybcellcd4+tcellandcirculatingfollicularhelpertcellresponsestoanonreplicatingmodifiedvacciniaankaravaccine‏ ‎‡A  Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine‏ ‎‡9  1‏
919 ‎‡a  phase2trialinadultsofconcurrentorsequential2009pandemich1n1and20092010seasonaltrivalentinfluenzavaccinations‏ ‎‡A  Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations‏ ‎‡9  1‏
919 ‎‡a  phase2randomizeddoubleblindedcomparisonofasinglehighdose5108tcid50ofmodifiedvacciniaankaracomparedtoastandarddose1108tcid50inhealthyvaccinianaiveindividuals‏ ‎‡A  Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals‏ ‎‡9  1‏
919 ‎‡a  persistenceofantibodytoinfluenzaah5n1vaccinevirusimpactofas03adjuvant‏ ‎‡A  Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant‏ ‎‡9  1‏
919 ‎‡a  lowdoseaspirinusedoesnotdiminishtheimmuneresponsetomonovalenth1n1influenzavaccineinolderadults‏ ‎‡A  Low-dose aspirin use does not diminish the immune response to monovalent H1N1 influenza vaccine in older adults‏ ‎‡9  1‏
919 ‎‡a  impactofbodymassindexonimmunogenicityofpandemich1n1vaccineinchildrenandadults‏ ‎‡A  Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.‏ ‎‡9  1‏
919 ‎‡a  immunogenicityofavianinfluenzaaanhui012005h5n1vaccinewithmf59adjuvantarandomizedclinicaltrial‏ ‎‡A  Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial‏ ‎‡9  1‏
919 ‎‡a  immunogenicityandsafetyofvaryingdosagesofamonovalent2009h1n1influenzavaccinegivenwithandwithoutas03adjuvantsysteminhealthyadultsandolderpersons‏ ‎‡A  Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons‏ ‎‡9  1‏
919 ‎‡a  immunogenicityandsafetyof4differentdosingregimensofanthraxvaccineadsorbedforpostexposureprophylaxisforanthraxinadults‏ ‎‡A  Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults‏ ‎‡9  1‏
919 ‎‡a  immunogenicityandsafetyofdifferentdoseschedulesandantigendosesofanmf59adjuvantedh7n9vaccineinhealthyadultsaged65yearsandolder‏ ‎‡A  Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older‏ ‎‡9  1‏
919 ‎‡a  immuneresponsesofhealthysubjectstoasingledoseofintramuscularinactivatedinfluenzaavietnam12032004h5n1vaccineafterprimingwithanantigenicvariant‏ ‎‡A  Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.‏ ‎‡9  1‏
919 ‎‡a  highdosetrivalentinfluenzavaccinecomparedtostandarddosevaccineinpatientswithrheumatoidarthritisreceivingtnfalphainhibitortherapyandhealthycontrolsresultsofthedmid100076randomizedclinicaltrial‏ ‎‡A  High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial‏ ‎‡9  1‏
919 ‎‡a  evaluationofagerelateddifferencesintheimmunogenicityofag9h9n2influenzavaccine‏ ‎‡A  Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine‏ ‎‡9  1‏
919 ‎‡a  enhancedpotencyanddurabilityofantibodyresponsetoseasonaltrivalentinactivatedinfluenzavaccinetivcombinedwithanovelwaterinoiladjuvantsystematreducedhemagglutininhadoses‏ ‎‡A  Enhanced Potency and Durability of Antibody Response to Seasonal Trivalent Inactivated Influenza Vaccine (TIV) Combined with a Novel Water-in-Oil Adjuvant System at Reduced Hemagglutinin (HA) Doses.‏ ‎‡9  1‏
919 ‎‡a  enhancedpotencyanddurabilityofantibodyresponsetoseasonaltrivalentinactivatedinfluenzavaccine‏ ‎‡A  Enhanced Potency and Durability of Antibody Response to Seasonal Trivalent Inactivated Influenza Vaccine‏ ‎‡9  1‏
919 ‎‡a  effectsofadjuvantsonthesafetyandimmunogenicityofanavianinfluenzah5n1vaccineinadults‏ ‎‡A  Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults‏ ‎‡9  1‏
919 ‎‡a  effectofvaryingdosesofamonovalenth7n9influenzavaccinewithandwithoutas03andmf59adjuvantsonimmuneresponsearandomizedclinicaltrial‏ ‎‡A  Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial‏ ‎‡9  1‏
919 ‎‡a  effectofrecentseasonalinfluenzavaccinationonserumantibodyresponsestocandidatepandemicinfluenzaah5n1vaccinesametaanalysis‏ ‎‡A  Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis‏ ‎‡9  1‏
919 ‎‡a  directcomparisonofaninactivatedsubvirioninfluenzaavirussubtypeh5n1vaccineadministeredbytheintradermalandintramuscularroutes‏ ‎‡A  Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes‏ ‎‡9  1‏
919 ‎‡a  determinationofthe50humaninfectiousdosefornorwalkvirus‏ ‎‡A  Determination of the 50% human infectious dose for Norwalk virus‏ ‎‡9  1‏
919 ‎‡a  comparisonoftheimmunogenicityandsafetyofasplitvirioninactivatedtrivalentinfluenzavaccinefluzoneadministeredbyintradermalandintramuscularrouteinhealthyadults‏ ‎‡A  Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults‏ ‎‡9  1‏
919 ‎‡a  comparisonoflyophilizedversusliquidmodifiedvacciniaankaramvaformulationsandsubcutaneousversusintradermalroutesofadministrationinhealthyvaccinianaivesubjects‏ ‎‡A  Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects‏ ‎‡9  1‏
919 ‎‡a  clinicalandimmunologicresponsestomultipledosesofimvamunemodifiedvacciniaankarafollowedbydryvaxchallenge‏ ‎‡A  Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge‏ ‎‡9  1‏
919 ‎‡a  clinicalandimmunologicresponsestomultipledosesofimvamune‏ ‎‡A  Clinical and immunologic responses to multiple doses of IMVAMUNE‏ ‎‡9  1‏
919 ‎‡a  clinicalandimmuneresponsestoinactivatedinfluenzaah1n1pdm09vaccineinchildren‏ ‎‡A  Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.‏ ‎‡9  1‏
919 ‎‡a  cellmediatedimmuneresponsesfollowingrevaccinationwithaninfluenzaah5n1vaccine‏ ‎‡A  Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine‏ ‎‡9  1‏
919 ‎‡a  cellbasedsystemsbiologyanalysisofhumanas03adjuvantedh5n1avianinfluenzavaccineresponsesaphase1randomizedcontrolledtrial‏ ‎‡A  Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial‏ ‎‡9  1‏
919 ‎‡a  baselinelevelsofinfluenzaspecificbcellsandtcellresponsesmodulatehumanimmuneresponsestoswinevariantinfluenzaah3n2vaccine‏ ‎‡A  Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine‏ ‎‡9  1‏
919 ‎‡a  assessmentofsafetyinnewbornsofmothersparticipatinginclinicaltrialsofvaccinesadministeredduringpregnancy‏ ‎‡A  Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy.‏ ‎‡9  1‏
919 ‎‡a  alkalinecpdandthepreservationofrbc23dpg‏ ‎‡A  Alkaline CPD and the preservation of RBC 2,3-DPG.‏ ‎‡9  1‏
919 ‎‡a  phase2randomizedcontroltrialofgroupbstreptococcusgbstype3capsularpolysaccharidetetanustoxoidgbs3ttvaccinetopreventvaginalcolonizationwithgbs3‏ ‎‡A  A Phase II Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide -Tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization with GBS III‏ ‎‡9  1‏
919 ‎‡a  phase1doseescalationtrialinadultsof3recombinantattenuatedsalmonellatyphivaccinevectorsproducingstreptococcuspneumoniaesurfaceproteinantigenpspa‏ ‎‡A  A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA.‏ ‎‡9  1‏
919 ‎‡a  994as03adjuvantedh5n1avianinfluenzavaccinemodulatesearlyinnateimmunesignaturesinperipheralbloodmononuclearcells‏ ‎‡A  994. AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Peripheral Blood Mononuclear Cells‏ ‎‡9  1‏
996 ‎‡2  LC|n 2019046635‏
996 ‎‡2  ISNI|0000000074062846‏
996 ‎‡2  CAOONL|ncf10385815‏
996 ‎‡2  ISNI|000000037132331X‏
996 ‎‡2  LC|n 2015025081‏
996 ‎‡2  ISNI|0000000399819886‏
996 ‎‡2  BIBSYS|97024124‏
996 ‎‡2  LC|n 80058551‏
996 ‎‡2  LC|nb 90051044‏
996 ‎‡2  RERO|A003371731‏
996 ‎‡2  PTBNP|226587‏
996 ‎‡2  LC|nb2017006731‏
996 ‎‡2  ISNI|0000000117554964‏
996 ‎‡2  LC|n 80107555‏
996 ‎‡2  RERO|A003371730‏
996 ‎‡2  ISNI|0000000037759476‏
996 ‎‡2  LC|no2009167576‏
996 ‎‡2  ISNI|0000000499314519‏
996 ‎‡2  J9U|987007314616905171‏
996 ‎‡2  BIBSYS|90395926‏
996 ‎‡2  SUDOC|073920851‏
996 ‎‡2  LC|n 2015022418‏
996 ‎‡2  LC|n 96072652‏
996 ‎‡2  ISNI|0000000498347757‏
996 ‎‡2  ISNI|0000000034568308‏
996 ‎‡2  LC|no2015106629‏
996 ‎‡2  DBC|87097968435374‏
996 ‎‡2  RERO|A006085000‏
996 ‎‡2  NYNYRILM|209235‏
996 ‎‡2  ISNI|0000000396800696‏
996 ‎‡2  SUDOC|248417061‏
996 ‎‡2  LC|n 89659770‏
996 ‎‡2  BIBSYS|7029034‏
996 ‎‡2  BIBSYS|8070207‏
996 ‎‡2  LC|n 2001105417‏
996 ‎‡2  CAOONL|ncf11334362‏
996 ‎‡2  ISNI|0000000021074288‏
996 ‎‡2  BIBSYS|2051850‏
996 ‎‡2  LC|no2018072658‏
996 ‎‡2  LC|n 87144081‏
996 ‎‡2  NTA|308011309‏
996 ‎‡2  ISNI|0000000114600697‏
996 ‎‡2  ISNI|0000000364179508‏
996 ‎‡2  LC|no2013003138‏
996 ‎‡2  NTA|069750181‏
996 ‎‡2  N6I|vtls000086517‏
996 ‎‡2  B2Q|0000346451‏
996 ‎‡2  J9U|987007436855905171‏
996 ‎‡2  LC|no2016024574‏
996 ‎‡2  ISNI|0000000428730662‏
996 ‎‡2  NUKAT|n 2012069689‏
996 ‎‡2  LC|no2017081990‏
996 ‎‡2  NDL|001176377‏
996 ‎‡2  LC|n 2004101679‏
996 ‎‡2  ISNI|0000000393026893‏
996 ‎‡2  SELIBR|317474‏
996 ‎‡2  PLWABN|9812829358205606‏
996 ‎‡2  BIBSYS|90140812‏
996 ‎‡2  SUDOC|121639401‏
996 ‎‡2  NDL|00443325‏
996 ‎‡2  N6I|vtls000097503‏
996 ‎‡2  ISNI|0000000042306260‏
996 ‎‡2  ISNI|0000000448101839‏
996 ‎‡2  LC|n 88175104‏
996 ‎‡2  LC|nb2001065243‏
996 ‎‡2  ISNI|0000000393001987‏
996 ‎‡2  NTA|172731577‏
996 ‎‡2  PLWABN|9810541215405606‏
996 ‎‡2  BIBSYS|90361438‏
996 ‎‡2  DNB|1253303894‏
996 ‎‡2  ISNI|0000000030392624‏
996 ‎‡2  LC|nb2017020002‏
996 ‎‡2  LC|no2022042506‏
996 ‎‡2  NUKAT|n 01722535‏
996 ‎‡2  BIBSYS|90064943‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏